View in EDS

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.

Saved in:
Bibliographic Details
Title: Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Authors: Rodler, Eve1 (AUTHOR), Sharma, Priyanka1,2 (AUTHOR) psharma2@kumc.edu, Barlow, William E3 (AUTHOR), Gralow, Julie R4 (AUTHOR), Puhalla, Shannon L5 (AUTHOR), Anders, Carey K6 (AUTHOR), Goldstein, Lori7 (AUTHOR), Tripathy, Debu8 (AUTHOR), Brown-Glaberman, Ursa A9,10 (AUTHOR), Huynh, Thu-Tam11,12 (AUTHOR), Szyarto, Christopher S13,14 (AUTHOR), Godwin, Andrew K15 (AUTHOR), Pathak, Harsh B15 (AUTHOR), Swisher, Elizabeth M16 (AUTHOR), Radke, Marc R16 (AUTHOR), Timms, Kirsten M17 (AUTHOR), Lew, Danika L3 (AUTHOR), Miao, Jieling3 (AUTHOR), Pusztai, Lajos18 (AUTHOR), Hayes, Daniel F19 (AUTHOR)
Source: Lancet Oncology. Feb2023, Vol. 24 Issue 2, p162-174. 13p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(22)00739-2